Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX versus gemcitabine + nab-paclitaxel for unresectable pancreatic cancer
ChiCTR2000034870Phase 4Recruiting
- Sponsor
- Wannan Medical College
- Start
- Jul 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of oxaliplatin, folinic acid, irinotecan, fluorouracil, gemcitabine and 1 more in pancreatic cancer (PC) (2 arms), sponsored by Wannan Medical College. Primary endpoint: overall survival. Started Jul 2020; status: recruiting.
02
Drugs
oxaliplatinfolinic acidirinotecanfluorouracilgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2000034870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034870.